These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34815180)

  • 21. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
    Xu JY; Li ZP; Zhang L; Ji G
    World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice.
    Wang R; Ren Y; Bao T; Wang T; Li Y; Liu Y; Zhang X; Yang S; Wang H
    Biochem Biophys Res Commun; 2022 Apr; 600():156-162. PubMed ID: 35240510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
    Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
    Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
    Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
    Chiang JYL; Ferrell JM
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
    Zhou W; Anakk S
    Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
    Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of FXR in the development of NAFLD and intervention strategies of small molecules.
    Long J; Xu Y; Zhang X; Wu B; Wang C
    Arch Biochem Biophys; 2024 Jul; 757():110024. PubMed ID: 38703803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bile acid receptors in non-alcoholic fatty liver disease.
    Li Y; Jadhav K; Zhang Y
    Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery.
    Browning MG; Pessoa BM; Khoraki J; Campos GM
    Curr Obes Rep; 2019 Jun; 8(2):175-184. PubMed ID: 30847736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
    Gottlieb A; Canbay A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis.
    Kuang J; Wang J; Li Y; Li M; Zhao M; Ge K; Zheng D; Cheung KCP; Liao B; Wang S; Chen T; Zhang Y; Wang C; Ji G; Chen P; Zhou H; Xie C; Zhao A; Jia W; Zheng X; Jia W
    Cell Metab; 2023 Oct; 35(10):1752-1766.e8. PubMed ID: 37591244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bile acids and their receptors in metabolic disorders.
    Fiorucci S; Distrutti E; Carino A; Zampella A; Biagioli M
    Prog Lipid Res; 2021 Apr; 82():101094. PubMed ID: 33636214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
    Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
    Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.